Literature DB >> 34298803

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment.

Valerio Nardone1,2, Luca Boldrini3, Roberta Grassi1,2, Davide Franceschini4, Ilaria Morelli5, Carlotta Becherini5, Mauro Loi6, Daniela Greto6, Isacco Desideri6,7.   

Abstract

INTRODUCTION: Neoadjuvant radiotherapy is currently used mainly in locally advanced rectal cancer and sarcoma and in a subset of non-small cell lung cancer and esophageal cancer, whereas in other diseases it is under investigation. The evaluation of the efficacy of the induction strategy is made possible by performing imaging investigations before and after the neoadjuvant therapy and is usually challenging. In the last decade, texture analysis (TA) has been developed to help the radiologist to quantify and identify the parameters related to tumor heterogeneity, which cannot be appreciated by the naked eye. The aim of this narrative is to review the impact of TA on the prediction of response to neoadjuvant radiotherapy and or chemoradiotherapy.
MATERIALS AND METHODS: Key references were derived from a PubMed query. Hand searching and ClinicalTrials.gov were also used.
RESULTS: This paper contains a narrative report and a critical discussion of radiomics approaches in different fields of neoadjuvant radiotherapy, including esophageal cancer, lung cancer, sarcoma, and rectal cancer.
CONCLUSIONS: Radiomics can shed a light on the setting of neoadjuvant therapies that can be used to tailor subsequent approaches or even to avoid surgery in the future. At the same, these results need to be validated in prospective and multicenter trials.

Entities:  

Keywords:  neoadjuvant radiotherapy; radiomics; texture analysis

Year:  2021        PMID: 34298803     DOI: 10.3390/cancers13143590

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Sergio Venanzio Setola; Andrea Belli; Alessandro Ottaiano; Guglielmo Nasti; Michelearcangelo La Porta; Ginevra Danti; Salvatore Cappabianca; Carmen Cutolo; Antonella Petrillo; Francesco Izzo
Journal:  Radiol Med       Date:  2021-11-29       Impact factor: 3.469

2.  Delta radiomics: a systematic review.

Authors:  Valerio Nardone; Alfonso Reginelli; Roberta Grassi; Luca Boldrini; Giovanna Vacca; Emma D'Ippolito; Salvatore Annunziata; Alessandra Farchione; Maria Paola Belfiore; Isacco Desideri; Salvatore Cappabianca
Journal:  Radiol Med       Date:  2021-12-04       Impact factor: 3.469

3.  MRI Radiomics in Prostate Cancer: A Reliability Study.

Authors:  Fabrizio Urraro; Valerio Nardone; Alfonso Reginelli; Carlo Varelli; Antonio Angrisani; Vittorio Patanè; Luca D'Ambrosio; Pietro Roccatagliata; Gaetano Maria Russo; Luigi Gallo; Marco De Chiara; Lucia Altucci; Salvatore Cappabianca
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 6.244

Review 4.  Clinical Perspectives for 18F-FDG PET Imaging in Pediatric Oncology: Μetabolic Tumor Volume and Radiomics.

Authors:  Vassiliki Lyra; Sofia Chatziioannou; Maria Kallergi
Journal:  Metabolites       Date:  2022-02-28

5.  The Utility of ADC First-Order Histogram Features for the Prediction of Metachronous Metastases in Rectal Cancer: A Preliminary Study.

Authors:  Bianca Boca Petresc; Cosmin Caraiani; Loredana Popa; Andrei Lebovici; Diana Sorina Feier; Carmen Bodale; Mircea Marian Buruian
Journal:  Biology (Basel)       Date:  2022-03-16

Review 6.  Radiomics-based prediction of two-year clinical outcome in locally advanced cervical cancer patients undergoing neoadjuvant chemoradiotherapy.

Authors:  Rosa Autorino; Benedetta Gui; Giulia Panza; Luca Boldrini; Davide Cusumano; Luca Russo; Alessia Nardangeli; Salvatore Persiani; Maura Campitelli; Gabriella Ferrandina; Gabriella Macchia; Vincenzo Valentini; Maria Antonietta Gambacorta; Riccardo Manfredi
Journal:  Radiol Med       Date:  2022-03-24       Impact factor: 6.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.